Welcome to our dedicated page for ImmunoGen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on ImmunoGen stock.
ImmunoGen, Inc. (NASDAQ: IMGN) is a pioneering clinical-stage biotechnology company focused on developing targeted anticancer therapeutics using proprietary antibody-drug conjugate (ADC) technology. The company's mission is to create groundbreaking treatments that improve outcomes for cancer patients.
ImmunoGen's flagship product, ELAHERE® (mirvetuximab soravtansine-gynx), is a first-in-class ADC that has received accelerated approval from the U.S. FDA for treating adult patients with folate receptor alpha (FRα) positive, platinum-resistant ovarian cancer. This innovative therapy is the first targeted medicine to demonstrate a meaningful survival benefit in this patient group.
Recent News: On November 30, 2023, AbbVie Inc. (NYSE: ABBV) and ImmunoGen announced a definitive agreement under which AbbVie will acquire ImmunoGen for $31.26 per share in cash. This acquisition, valued at approximately $10.1 billion, is expected to close in mid-2024, pending shareholder and regulatory approvals.
ImmunoGen has a robust pipeline of next-generation ADCs, including IMGN-151, designed for ovarian cancer, and Pivekimab sunirine, targeting rare blood cancer BPDCN. The company's technology is also utilized in Roche's marketed product, Kadcyla, highlighting its industry-wide impact.
With its innovative approaches and strategic partnerships, ImmunoGen is at the forefront of developing cutting-edge cancer therapies aimed at disrupting the progression of cancer and offering patients more good days.
- Lead Product: ELAHERE® for platinum-resistant ovarian cancer
- Pipeline Products: IMGN-151, Pivekimab sunirine
- Partnerships: Roche, AbbVie
- Technology: Proprietary antibody-drug conjugate (ADC) technology
- Financial Condition: Recently valued at $10.1 billion in acquisition deal with AbbVie
- Website: www.immunogen.com
ImmunoGen, Inc. (NASDAQ: IMGN) announced the appointment of Isabel Kalofonos as Senior Vice President and Chief Commercial Officer. This move comes at a pivotal time following the November approval of ELAHERE for platinum-resistant ovarian cancer. CEO Mark Enyedy emphasized Kalofonos's extensive experience in global commercialization will enhance their launch execution and drive ELAHERE's market adoption. Previously, she helped launch a drug at Galderma and led the TAKHZYRO launch at Takeda Pharmaceuticals.
Kalofonos expressed enthusiasm for the role, citing strong physician reception for ELAHERE and the company's ambitions to expand its portfolio. ImmunoGen aims to establish ELAHERE as standard care and broaden its impact in Europe.
ImmunoGen Inc. (NASDAQ: IMGN) announced a conference call scheduled for April 28, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 operating results. The call will also include a business update from management. Interested parties can access the call through registration, and a replay will be available on the company’s website afterward. ImmunoGen specializes in developing antibody-drug conjugates (ADCs) aimed at improving outcomes for cancer patients, focusing on targeted therapies that enhance anti-tumor activity and tolerability.
ImmunoGen, Inc. has secured a term loan financing facility worth
FAQ
What is the market cap of ImmunoGen (IMGN)?
What does ImmunoGen, Inc. specialize in?
What is ELAHERE®?
Who is acquiring ImmunoGen, Inc.?
What is the significance of the acquisition by AbbVie?
What other products are in ImmunoGen's pipeline?
What technology does ImmunoGen use?
What is Kadcyla?
When is the acquisition by AbbVie expected to close?
Where can I find more information about ImmunoGen, Inc.?
What is the focus of ImmunoGen's research and development?
